Investing in pharmaceutical companies with diversified revenue bases and strong R&D pipelines could be a lucrative strategy.

In this week’s edition of InnovationRx, we look at the battle for Metsera, the departure of FDA’s top drug regulator, Kimberly-Clark’s $40 billion Kenvue deal, and more.

Intensifying competition, pricing pressure and copycat versions of its weight-loss drugs are holding back sales at the pharma ...

This article was reviewed by Darragh O’Carroll, MD. GLP-1 for Weight Loss: Everything You Need to Know Key takeaways: GLP-1s ...

Wegovy-maker Novo Nordisk presented new data on Wednesday showing its experimental weight-loss pill improved blood sugar ...